Abstract
Mutations in the pivotal metabolic isocitrate dehydrogenase (IDH) enzymes are recognized to drive the molecular footprint of diffuse gliomas, and patients with IDH mutant gliomas have overall favorable outcomes compared to patients with IDH wild-type tumors. However, survival still varies widely among patients with IDH mutated tumors. Here, we aimed to characterize molecular signatures that explain the range of IDH mutant gliomas. By integrating matched epigenome-wide methylome, transcriptome, and global metabolome data in 154 patients with gliomas, we identified a group of IDH mutant gliomas with globally altered metabolism that resembled IDH wild-type tumors. IDH-mutant gliomas with altered metabolism have significantly shorter overall survival from their IDH mutant counterparts that is not fully accounted for by recognized molecular prognostic markers of CDKN2A/B loss and glioma CpG Island Methylator Phenotype (GCIMP) status. IDH-mutant tumors with dysregulated metabolism harbored distinct epigenetic alterations that converged to drive proliferative and stem-like transcriptional profiles, providing a window to target novel dependencies in gliomas.
Graphical Abstract
Similar content being viewed by others
Data availability
Raw methylation (idat files) from Universiy Health Network (UHN) for the IDH-Mutant Gliomas have been deposited to the European Genome-Phenome Archive with the dataset identifier of EGAS00001006961 (https://wwwdev.ebi.ac.uk/ega/studies/EGAS00001006961). The Cancer Genome Atlas (TCGA) dataset is open access. Additional idats for the IDH wild type cohort, RNAseq data and metabolomic data from this study can be made available upon request to our corresponding author (gelareh.zadeh@uhn.ca).
References
Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD et al (2014) Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30:1363–1369. https://doi.org/10.1093/bioinformatics/btu049
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108–112. https://doi.org/10.1038/nature08460
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E et al (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576:112–120. https://doi.org/10.1038/s41586-019-1775-1
Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608. https://doi.org/10.1007/s00401-020-02127-9
Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, Cooper LAD et al (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/NEJMoa1402121
Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. https://doi.org/10.1016/j.cell.2013.09.034
Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. https://doi.org/10.1038/nature26000
Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M et al (2018) Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol 136:181–210. https://doi.org/10.1007/s00401-018-1879-y
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA et al (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028
Chinnaiyan P, Kensicki E, Bloom G, Prabhu A, Sarcar B, Kahali S et al (2012) The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res 72:5878–5888. https://doi.org/10.1158/0008-5472.CAN-12-1572-T
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15–21. https://doi.org/10.1093/bioinformatics/bts635
Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656–6667. https://doi.org/10.1021/ac901536h
Feber A, Guilhamon P, Lechner M, Fenton T, Wilson GA, Thirlwell C et al (2014) Using high-density DNA methylation arrays to profile copy number alterations. Genome Biol 15:R30. https://doi.org/10.1186/gb-2014-15-2-r30
de Hoon MJL, Imoto S, Nolan J, Miyano S (2004) Open source clustering software. Bioinformatics 20:1453–1454. https://doi.org/10.1093/bioinformatics/bth078
Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, Noushmehr H, Verhaak RGW (2023) Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro Oncol 25:1721–1723
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352
Liao Y, Smyth GK, Shi W (2019) The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res 47:e47. https://doi.org/10.1093/nar/gkz114
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
Mah CK, Mesirov JP, Chavez L (2018) An accessible GenePattern notebook for the copy number variation analysis of Illumina Infinium DNA methylation arrays. F1000Research 7. doi: https://doi.org/10.12688/f1000research.16338.1
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN et al (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15. https://doi.org/10.1016/j.cell.2018.03.034
Müller F-J, Laurent LC, Kostka D, Ulitsky I, Williams R, Lu C et al (2008) Regulatory networks define phenotypic classes of human stem cell lines. Nature 455:401–405. https://doi.org/10.1038/nature07213
Nassiri F, Chakravarthy A, Feng S, Shen SY, Nejad R, Zuccato JA et al (2020) Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nat Med 26:1044–1047. https://doi.org/10.1038/s41591-020-0932-2
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522. https://doi.org/10.1016/j.ccr.2010.03.017
Prabhu AH, Kant S, Kesarwani P, Ahmed K, Forsyth P, Nakano I et al (2019) Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma. Neuro Oncol 21:337–347. https://doi.org/10.1093/neuonc/noy185
RC T (2013) R: A Language and Environment for Statistical Computing
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https://doi.org/10.1093/nar/gkv007
Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G et al (2011) Integrative genomics viewer. Nat Biotechnol 29:24–26
Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140. https://doi.org/10.1093/bioinformatics/btp616
Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D et al (2018) Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 563:579–583. https://doi.org/10.1038/s41586-018-0703-0
Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166. https://doi.org/10.1007/s00401-018-1849-4
de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A et al (2018) A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. Cell Rep 23:637–651. https://doi.org/10.1016/j.celrep.2018.03.107
Teschendorff AE (2020) A comparison of epigenetic mitotic-like clocks for cancer risk prediction. Genome Med 12:56. https://doi.org/10.1186/s13073-020-00752-3
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483. https://doi.org/10.1038/nature10866
Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DIS, Zairis S et al (2016) Clonal evolution of glioblastoma under therapy. Nat Genet 48:768–776. https://doi.org/10.1038/ng.3590
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710
Yan X, Ma L, Yi D, Yoon J, Diercks A, Foltz G et al (2011) A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A 108:1591–1596. https://doi.org/10.1073/pnas.1018696108
Yang Z, Wong A, Kuh D, Paul DS, Rakyan VK, Leslie RD et al (2016) Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol 17:205. https://doi.org/10.1186/s13059-016-1064-3
Zhou W, Dinh HQ, Ramjan Z, Weisenberger DJ, Nicolet CM, Shen H et al (2018) DNA methylation loss in late-replicating domains is linked to mitotic cell division. Nat Genet 50:591–602. https://doi.org/10.1038/s41588-018-0073-4
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no potential conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nassiri, F., Ajisebutu, A., Patil, V. et al. Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype. Acta Neuropathol 147, 68 (2024). https://doi.org/10.1007/s00401-024-02713-1
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00401-024-02713-1